Cargando…
Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology
BACKGROUND: Diabetes is a complex metabolic disease characterized by hyperglycemia, plaguing the whole world. However, the action mode of multi-component and multi-target for traditional Chinese medicine (TCM) could be a promising treatment of diabetes mellitus. According to the previous research, t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672844/ https://www.ncbi.nlm.nih.gov/pubmed/33292335 http://dx.doi.org/10.1186/s13020-020-00401-2 |
_version_ | 1783611216392880128 |
---|---|
author | Song, Yunfei Yang, Jianbo Jing, Wenguang Wang, Qi Liu, Yue Cheng, Xianlong Ye, Fei Tian, Jinying Wei, Feng Ma, Shuangcheng |
author_facet | Song, Yunfei Yang, Jianbo Jing, Wenguang Wang, Qi Liu, Yue Cheng, Xianlong Ye, Fei Tian, Jinying Wei, Feng Ma, Shuangcheng |
author_sort | Song, Yunfei |
collection | PubMed |
description | BACKGROUND: Diabetes is a complex metabolic disease characterized by hyperglycemia, plaguing the whole world. However, the action mode of multi-component and multi-target for traditional Chinese medicine (TCM) could be a promising treatment of diabetes mellitus. According to the previous research, the TCM of Polygonum multiflorum (PM) showed noteworthy hypoglycemic effect. Up to now, its hypoglycemic active ingredients and mechanism of action are not yet clear. In this study, network pharmacology was employed to elucidate the potential bioactive compounds and hypoglycemic mechanism of PM. METHODS: First, the compounds with good pharmacokinetic properties were screened from the self-established library of PM, and the targets of these compounds were predicted and collected through database. Relevant targets of diabetes were summarized by searching database. The intersection targets of compound-targets and disease-targets were obtained soon. Secondly, the interaction net between the compounds and the filtered targets was established. These key targets were enriched and analyzed by protein–protein interactions (PPI) analysis, molecular docking verification. Thirdly, the key genes were used to find the biologic pathway and explain the therapeutic mechanism by genome ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analysis. Lastly, the part of potential bioactive compounds were under enzyme activity inhibition tests. RESULTS: In this study, 29 hypoglycemic components and 63 hypoglycemic targets of PM were filtrated based on online network database. Then the component-target interaction network was constructed and five key components resveratrol, apigenin, kaempferol, quercetin and luteolin were further obtained. Sequential studies turned out, AKT1, EGFR, ESR1, PTGS2, MMP9, MAPK14, and KDR were the common key targets. Docking studies indicated that the bioactive compounds could stably bind the pockets of target proteins. There were 38 metabolic pathways, including regulation of lipolysis in adipocytes, prolactin signaling pathway, TNF signaling pathway, VEGF signaling pathway, FoxO signaling pathway, estrogen signaling pathway, linoleic acid metabolism, Rap1 signaling pathway, arachidonic acid metabolism, and osteoclast differentiation closely connected with the hypoglycemic mechanism of PM. And the enzyme activity inhibition tests showed the bioactive ingredients have great hypoglycemic activity. CONCLUSION: In summary, the study used systems pharmacology to elucidate the main hypoglycemic components and mechanism of PM. The work provided a scientific basis for the further hypoglycemic effect research of PM and its monomer components, but also provided a reference for the secondary development of PM. |
format | Online Article Text |
id | pubmed-7672844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76728442020-11-19 Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology Song, Yunfei Yang, Jianbo Jing, Wenguang Wang, Qi Liu, Yue Cheng, Xianlong Ye, Fei Tian, Jinying Wei, Feng Ma, Shuangcheng Chin Med Research BACKGROUND: Diabetes is a complex metabolic disease characterized by hyperglycemia, plaguing the whole world. However, the action mode of multi-component and multi-target for traditional Chinese medicine (TCM) could be a promising treatment of diabetes mellitus. According to the previous research, the TCM of Polygonum multiflorum (PM) showed noteworthy hypoglycemic effect. Up to now, its hypoglycemic active ingredients and mechanism of action are not yet clear. In this study, network pharmacology was employed to elucidate the potential bioactive compounds and hypoglycemic mechanism of PM. METHODS: First, the compounds with good pharmacokinetic properties were screened from the self-established library of PM, and the targets of these compounds were predicted and collected through database. Relevant targets of diabetes were summarized by searching database. The intersection targets of compound-targets and disease-targets were obtained soon. Secondly, the interaction net between the compounds and the filtered targets was established. These key targets were enriched and analyzed by protein–protein interactions (PPI) analysis, molecular docking verification. Thirdly, the key genes were used to find the biologic pathway and explain the therapeutic mechanism by genome ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analysis. Lastly, the part of potential bioactive compounds were under enzyme activity inhibition tests. RESULTS: In this study, 29 hypoglycemic components and 63 hypoglycemic targets of PM were filtrated based on online network database. Then the component-target interaction network was constructed and five key components resveratrol, apigenin, kaempferol, quercetin and luteolin were further obtained. Sequential studies turned out, AKT1, EGFR, ESR1, PTGS2, MMP9, MAPK14, and KDR were the common key targets. Docking studies indicated that the bioactive compounds could stably bind the pockets of target proteins. There were 38 metabolic pathways, including regulation of lipolysis in adipocytes, prolactin signaling pathway, TNF signaling pathway, VEGF signaling pathway, FoxO signaling pathway, estrogen signaling pathway, linoleic acid metabolism, Rap1 signaling pathway, arachidonic acid metabolism, and osteoclast differentiation closely connected with the hypoglycemic mechanism of PM. And the enzyme activity inhibition tests showed the bioactive ingredients have great hypoglycemic activity. CONCLUSION: In summary, the study used systems pharmacology to elucidate the main hypoglycemic components and mechanism of PM. The work provided a scientific basis for the further hypoglycemic effect research of PM and its monomer components, but also provided a reference for the secondary development of PM. BioMed Central 2020-11-18 /pmc/articles/PMC7672844/ /pubmed/33292335 http://dx.doi.org/10.1186/s13020-020-00401-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Song, Yunfei Yang, Jianbo Jing, Wenguang Wang, Qi Liu, Yue Cheng, Xianlong Ye, Fei Tian, Jinying Wei, Feng Ma, Shuangcheng Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title | Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title_full | Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title_fullStr | Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title_full_unstemmed | Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title_short | Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology |
title_sort | systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of polygonum multiflorum based on network pharmacology |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672844/ https://www.ncbi.nlm.nih.gov/pubmed/33292335 http://dx.doi.org/10.1186/s13020-020-00401-2 |
work_keys_str_mv | AT songyunfei systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT yangjianbo systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT jingwenguang systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT wangqi systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT liuyue systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT chengxianlong systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT yefei systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT tianjinying systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT weifeng systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology AT mashuangcheng systemicelucidationonthepotentialbioactivecompoundsandhypoglycemicmechanismofpolygonummultiflorumbasedonnetworkpharmacology |